Can someone explain why it's taken so long to go from the success CAR-T had with non solid tumors, to getting an immunotherapy that indeed is effective against solid tumors?
"Success" for CAR-T is hazy, as many participants died from unrealized side effects, including new cancers.
>> The FDA indicated that patients and participants in clinical trials receiving CAR T-cell therapy should be monitored life-long for secondary malignancies.
>> Although CAR T-cells directed toward the HER2-expressing tumors have been extensively studied in clinical trials, safety concerns have emerged following the death of a CRC patient who received 1×1010 third-generation HER2-CAR T-cells.
